Diseases of the hepatobiliary system: focus on rational hepatotropic therapy

Authors

  • A.Yu. Filippova State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Dnipro, Ukraine

DOI:

https://doi.org/10.22141/2308-2097.53.3.2019.182866

Keywords:

hepatobiliary system, hepatotropic therapy, ursodeoxycholic acid, arginine glutamate

Abstract

The article presents data of the modern literature and our studies on the combined use of ursodeoxycholic acid and arginine glutamate in the pathology of the hepatobiliary system. Hepatobiliary diseases today remain a major socio-economic health problem worldwide, occupying a significant place in the structure of general somatic pathology in the clinic of internal medicine. Despite the apparent successes achieved over the past decades in the diagnosis and treatment of diseases of the hepatobiliary system, some issues are still not entirely resolved or there are contradictions about their treatment. It is known that not all hepatotropic drugs meet the requirements for active components that pathogenetically affect the links of pathological processes, which occur in the hepatobiliary tract. It is rather difficult to justify and systematize the treatment of hepatobiliary diseases with such a variety of causes of damage. The principles of modern therapy for most diseases of the hepatobiliary system include the administration of combinations of hepatotropic drugs. One of the most rational combinations of pharmacological agents for these purposes are preparations of ursodeoxycholic acid and arginine glutamate. These pharmacological agents are the drugs with the most substantial evidence base of clinical efficacy, significantly exceeding that of hepatotropic medications of other groups.

Downloads

Download data is not yet available.

References

Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology. 2012 Nov;143(5):1179-1187.e3. doi: 10.1053/j.gastro.2012.08.002.

Organisation for Economic Cooperation and Development (OECD). OECD Reviews of Health Systems: Kazakhstan 2018. Paris, France: OECD Publishing; 2018. 220 p.

Petrunko IL, Soklakova VI, Cherkasova AA, Sergeeva NV. Diseases of the digestive system: primary disability in the Irkutsk region. Acta Biomedica Scientifica. 2017;2(113):44-47. (in Russian).

Beliaeva IuN. Diseases of the digestive system as a medical and social problem. Bulletin of Medical Internet Conferences. 2013;3(3):566-568. (in Russian).

Stepanov YuM, Skirda IYu, Petishko OP. Digestive system diseases: the actual problem of clinical medicine. Gastroenterologìa. 2019;53(1):1-6. doi: 10.22141/2308-2097.53.1.2019.163450. (in Ukrainian).

Chepelevska LA, Slabkiy VG. The role of digestive diseases in falling employment potential of Ukraine. Ekonomіka і pravo ohoroni zdorov'â. 2017;(5):10-17. (in Ukrainian).

Chepelevska LA, Krapivina AA. Features of the Ukrainian population mortality from certain diseases of digestive system. Ukraïna. Zdorovʼâ nacìï. 2013;(1):54-58. (in Ukrainian).

Dzyuba AN, Chepelevska LA, Karamzina LA. Current trends in the mortality of the working-age population from diseases of the digestive system. Bulletin of Social Hygiene and Health Protection Organization of Ukraine. 2016;(67):24-29. (in Ukrainian).

Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease. Medicines (Basel). 2019 Mar 18;6(1). pii: E41. doi: 10.3390/medicines6010041.

Grechanyk M, Grechanyk N, Kuryata A. Lipid metabolism, endothelial function, parameters of elastic properties and inflammation in patients with coronary heart disease combined with hepatic steatosis depending from body mass index. Atherosclerosis. 2018;275:e148 doi: 10.1016/j.atherosclerosis.2018.06.438/.

Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: diagnostic biomarkers. World J Gastrointest Pathophysiol. 2017;8(2):11-26. doi: 10.4291/wjgp.v8.i2.11.

European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.

Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019 Feb;49(3):296-307. doi: 10.1111/apt.15063.

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367.

Filippova OYu. Dynamics of anthropometric and biochemical parameters under the influence of different treatment regimens in patients with non-alcoholic fatty liver disease in combination with obesity and pathology of the biliary tract. Likars'ka sprava. 2017;(1143):54-61. (in Ukrainian).

Nan YM, Fu N, Li WC, et al. An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017. Zhonghua Gan Zang Bing Za Zhi. 2017 Sep 20;25(9):687-694. doi: 10.3760/cma.j.issn.1007-3418.2017.09.008. (in Chinese).

Stepanov YuM, Filippova AYu. Influence body weight and concomitant pathology of the biliary tract on development and progression of lipid abnormalities in patients with nonalcoholic fatty liver disease in combination with obesity. Modern Gastroenterology. 2016;(90):7-15. (in Ukrainian).

Ahmed A, Wong RJ, Harrison SA. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2062-70. doi: 10.1016/j.cgh.2015.07.029.

Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016 Jan;17(1):68-80. doi: 10.1111/obr.12333.

Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014 May 27;6(5):263-73. doi: 10.4254/wjh.v6.i5.263.

Della Corte C, Mazzotta AR, Nobili V. Fatty liver disease and obesity in youth. Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):66-71. doi: 10.1097/MED.0000000000000221.

Stepanov YuM, Filippova AYu. Morphological basis for the assessment of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease associated with obesity and pathology of the biliary tract. Gastroenterologìa. 2017;51(3):196-204. doi: 10.22141/2308-2097.51.3.2017.112636. (in Ukrainian).

Filippova A. Non-alcoholic and alcoholic fatty liver disease in patients suffering from biliary tract pathology and obesity: clinical and functional aspects. Modern Science-Moderni vĕda. 2015;(4):134-149.

Thiele M, Rausch V, Fluhr G, et al. Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification. J Hepatol. 2018 May;68(5):1025-1032. doi: 10.1016/j.jhep.2017.12.029.

Lau K, Baumeister SE, Lieb W, et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. Aliment Pharmacol Ther. 2015 Mar;41(5):467-76. doi: 10.1111/apt.13067.

Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Jul 14;20(26):8393-406. doi: 10.3748/wjg.v20.i26.8393.

Allen AM, Kim WR. Epidemiology and Healthcare Burden of Acute-on-Chronic Liver Failure. Semin Liver Dis. 2016 May;36(2):123-6. doi: 10.1055/s-0036-1583201.

Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015 Jan;62(1):18-23. doi: 10.1016/j.jhep.2014.08.013.

Didenko VI, Oshmyanskaya NYu, Klenina IA. Morphological and biochemical evaluation of progression of chronic hepatitis associated with C virus. Gastroenterologìa. 2014;(52):37-41. doi: 10.22141/2308-2097.2.52.2014.81949. (in Russian).

Zavhorodnya NYu, Lukianenko OYu, Yagmur VB, Konenko IS. Gallbladder function and hepatic structural changes in children with nonalcoholic fatty liver disease. Gastroenterologìa. 2016;(60):38-43. doi:10.22141/2308-2097.2.60.2016.74731. (in Ukrainian).

Cotton PB, Elta GrH, Carter CR, Pasricha PJ, Corazziari ES. Rome IV. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology. 2016 May;150(6):1420-9.e2. doi: 10.1053/j.gastro.2016.02.033.

Di Ciaula A, Wang DQ, Portincasa P. Gallbladder and gastric motility in obese newborns, pre-adolescents and adults. J Gastroenterol Hepatol. 2012 Aug;27(8):1298-305. doi: 10.1111/j.1440-1746.2012.07149.x.

Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA. 2014 May;311(20):2101-9. doi: 10.1001/jama.2014.5220.

Vinnitskaya EV, Absandze KG, Arkhipova EV, Ivanov AN, Sbikina ES, Sandler YuG. Primary biliary cholangitis and ursodeoxycholic acid: therapy progress and challenges. Doktor Ru. 2019;(158):33-39. doi: 10.31550/1727-2378-2019-158-3-33-39. (in Russian).

Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis. 2015;33 Suppl 2:2-12. doi: 10.1159/000440705.

Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014 Aug;34(3):318-28. doi: 10.1055/s-0034-1383730.

Boonstra K, Kunst AE, Stadhouders PH, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014 Jul;34(6):e31-8. doi: 10.1111/liv.12434.

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022.

Dahlqvist G, Gaouar F, Carrat F, et al. Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. Hepatology. 2017 Jan;65(1):152-163. doi: 10.1002/hep.28859.

Hirschfield GM, Liu X, Xu C, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009 Jun 11;360(24):2544-55. doi: 10.1056/NEJMoa0810440.

Steinacher D, Claudel T, Trauner M. Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2017;35(3):282-287. doi: 10.1159/000454853.

Goroshko OA, Kukes VG, Prokofiev AB, Arkhipov VV, Demchenkova EYu. Clinico-pharmacological aspects of application of antioxidant drugs. International Journal of Applied and Fundamental Research. 2016;(4-5):905-912. (in Russian).

Makhov VM, Volodina TV, Panferov AS, Turko TV. Polynosological effects of ursodeoxycholic acid (UDCA). Practice of using. Meditsinskiy sovet. 2016;(14):62-67. (in Russian).

Kim DJ, Yoon S, Ji SC, et al. Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction. Sci Rep. 2018 Aug 8;8(1):11874. doi: 10.1038/s41598-018-30349-1.

Stepanov YuM, Kosynska SV. Features of ursodeoxycholic acid use in various pathologies of hepatobiliary tract and other organs and systems. Gastroenterologìa. 2014;(54):129-135. doi: 10.22141/2308-2097.4.54.2014.82088. (in Ukrainian).

Stokes CS, Gluud LL, Casper M, Lammert F. Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2014 Jul;12(7):1090-1100.e2; quiz e61. doi: 10.1016/j.cgh.2013.11.031.

Mueller M, Castro RE, Thorell A, et al. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver Int. 2018 Mar;38(3):523-531. doi: 10.1111/liv.13562.

Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: a meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016 Oct;95(40):e4949. doi: 10.1097/MD.0000000000004949.

Chistik T. A modern approach to the treatment of gastritis associated with bile reflux: focus on Ursokhol (ursodeoxycholic acid). Novosti Meditsiny i Farmatsii. 2014;(514):10-11. (in Russian).

Babak OYa, Fadeyenko HD, Frolov VM, Kruhlova OV. Pathogenetic substantiation of metabolically active agent L-arginine-L-glutamate for treatment of non-alcoholic fatty liver disease combined with non-calculous chronic cholecystitis. Liky Ukrai'ny. 2013;(168):29-33. (in Ukrainian).

Kharchenko NV, Anokhina GA, Kharchenko VV. The hepatic and extra-hepatic effects of the treatment complex with arginine-L and betaine in patients with metabolic syndrome. Modern Gastroenterology. 2015;(83):42-49. (in Ukrainian).

Duka I. The use of ready-made infusion of L-arginine glutamate Argitek in intensive care of emergency conditions. Zdorov’ja Ukrai'ny. Hirurgija, Ortopedija, Travmatologija, Intensyvna terapija. 2019;(35):39. (in Russian).

Downloads

Published

2021-09-06

How to Cite

Filippova, A. (2021). Diseases of the hepatobiliary system: focus on rational hepatotropic therapy. GASTROENTEROLOGY, 53(3), 188–195. https://doi.org/10.22141/2308-2097.53.3.2019.182866

Issue

Vol. 53 No. 3 (2019)

Section

Reviews and Lections

License

Copyright (c) 2019 A.Yu. Filippova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.